

SUPPLEMENTAL FIGURES





Figure S1, related to Figure 1. Absence of class-switched memory B cells in AD-*AICDA* and *UNG*-deficient patients resembles that in AID-deficient patients. (A) Representative dot plots for CD27 and IgM (upper row) or IgG and IgA (lower row) staining on purified CD20⁺ B cells. **(B)** Summary of the data shows absence of switched B cells in autosomal recessive *AICDA*-deficient (AID-def.) patients (n=17), autosomal dominant (AD)-*AICDA* patients (n=4) and *UNG*-deficient (*UNG*-def) patients (n=2), compared to healthy donors (HD, n=20) and asymptomatic healthy heterozygotes (*AICDA*^{+/-}, n=13).


A

New emigrant B cells



B

New emigrant B cells



C




Figure S2, related to Figure 1. Increased frequencies of autoreactive new emigrant B cells in AID-def. patients and *AICDA*^{+/-} healthy carriers. Recombinant antibodies expressed by CD19⁺CD21^{lo}CD10⁺IgM^{hi}CD27⁻ new emigrant B cells from AID-def. patients, asymptomatic healthy heterozygotes (*AICDA*^{+/-}), AD-AICDA and UNG-def. patients were tested by ELISA for polyreactivity against dsDNA, insulin and LPS (A) or HEp-2 reactivity (B). Solid lines show binding for each cloned recombinant antibody. Dotted lines show ED38-positive control. Horizontal lines show cutoff OD405 for positive

reactivity. Antibodies were considered polyreactive when they recognized all three antigens. For each individual, the frequency of polyreactive or HEP-2-reactive B cells are summarized in pie charts, with the number of antibodies tested shown in the center. (C) Autoreactive antibodies show various patterns of HEP-2 staining. Original magnification 40X, scale bar: 10 μ m. Please see also Figure 1.




Figure S3, related to Figure 5. Assessment of anti-BCL6, anti-MCL-1 and anti-active caspase-3 antibody specificity. Cytospin slides of sorted CD19⁺IgD⁺CD38⁻ CXCR4⁻ naïve B cells, CD19⁺IgD⁻CD38⁺CXCR4⁺ GC B cells and CD34⁻CD19⁺ fetal liver B cells were stained for (A) BCL-6, (B) MCL-1, (C) activated caspase-3 or concentration matched isotype control (green) and AID (red) and co-staining was quantified. Data is representative of 2 independent experiments. Original magnification 40X, scale bar: 10 μ m, Please see also Figure 5.





Figure S4, related to Figures 6 and 7. Central B-cell tolerance requires B-cell intrinsic AID expression. Antibodies from new emigrant B cells isolated from control humanized mice and sorted GFP- as well as GFP+ fractions expressing AID shRNA or control shRNA were tested by ELISA for reactivity against dsDNA, insulin and LPS (A) and HEP-2 cell lysates (B). Polyreactive antibodies reacted against all 3 antigens. Dotted lines show ED38-positive control. Horizontal lines show cutoff OD405 for positive reactivity. For each mouse, the frequency of reactive and non-reactive clones is summarized in pie charts, with the number of antibodies tested indicated in the center. Please see also Figures 6 and Figure 7.




Figure S5, related to Figures 6 and 7. Defective central B-cell tolerance in PFT α -treated mice. (A) Schematic diagram depicting PFT α injections in NSG humanized

mice. CD34⁺ hematopoietic stem cells (HSCs) were injected in recipients NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. Before sacrifice mice were injected with 50µg of PFTα daily for 7 days. Antibodies from new emigrant B cells isolated from one control and two PFTα-treated humanized NSG mice were tested by ELISA for polyreactivity (B) and HEp2-reactivity (C). Dotted lines show ED38-positive control. Horizontal lines show cutoff OD405 for positive reactivity. For each mouse, the frequency of reactive and non-reactive clones is summarized in pie charts, with the number of antibodies tested indicated in the center. Polyreactive antibodies reacted against all 3 antigens (dsDNA, insulin and LPS). The frequencies of polyreactive or HEp2-reactive new emigrant B cells in healthy donors and humanized mice treated or not with PFTα are summarized in the right panels. (D) The frequencies of anti-nuclear new emigrant B cells are compared between healthy donors and humanized mice treated or not with PFTα. (E) Anti-nuclear antibodies expressed by new emigrant B cells isolated from the PFTα-treated mice show various chromatin reactive and non-reactive nuclear reactivity. Original magnification 40X, scale bar 10µm. Please see also Figures 6 and Figure 7.




Figure S6, related to Figures 6 and 7. Increased frequency of AID⁺ bone marrow B cells in PFT α -treated mice. (A) Cytospin slides of CD19⁺ purified bone marrow cells were stained for IgM (green) and AID (red) and quantified for co-staining. White arrows show IgM⁺AID⁺ cells. Data are representative of 3 controls and 3 PFT α -treated mice. Original magnification 40X. scale bar 50 μ m (B) 300 CD19⁺ B cells (on 3 distinct fields) were analyzed for IgM and AID co-staining in control and PFT α -treated NSG humanized mice. Please see also Figures 6 and Figure 7.

Table S1, related to Figure 1. Characteristics of patients with *AICDA* or *UNG* mutations and heterozygote asympi

Patient number	Ethnic group	Sex	Age at diagnosis (yr)	Current age (yr)	Serum immunoglobins in mg/dl			Clinical Manifestations	Mutation in <i>AICDA</i> gene	Mutation in <i>AID</i>	Inheritance
					IgM	IgA	IgG				
AID-def.1*	Moroccan	M	5	22	240	<7	40	lymphoid hyperplasia, recurrent infections	203G>A / 175-184 del	W68X / H25-E58 del insV	AR
AID-def.2*	Moroccan	M	1	16	150	<7	<6	recurrent infections	203G>A / 175-184 del	W68X / H25-E58 del insV	AR
AID-def.4	Moroccan	M	1	20	100	<7	<6	lymphoid hyperplasia, recurrent infections	203G>A / del	W68X / 0	AR
AID-def.5	Turkish	M	11	21	1150	<5.8	264	lymphoid hyperplasia, recurrent infections	415A>G / 415A>G	M139V / M139V	AR
AID-def.6	Pakistani	M	4	4	4000	<7	<7	recurrent infections	394G>C / 394G>C	A132P / A132P	AR
AID-def.8	French Canadian	F	28	60	8830	<60	na	lymphoid hyperplasia, recurrent infections	334C>T / 334C>T	R112C / R112C	AR
AID-def.9	French Canadian	F	5	26	451	<30	178	lymphoid hyperplasia, recurrent infections	334C>T / 334C>T	R112C / R112C	AR
AID-def.10	French Canadian	F	3	22	621	40	60	recurrent infections	334C>T / 334C>T	R112C / R112C	AR
AID-def.11	French Canadian	M	2	50	6800	<60	na	recurrent infections	334C>T / 334C>T	R112C / R112C	AR
AID-def.17	Turkish	M		18					415A>G / 415 A>G	M139V / M139V	AR
AID-def.19	Kuwait	M	1	5	223	< 6	< 33	lymphoid hyperplasia, recurrent infections	254G>A / 254G>A	S85N / S85N	AR
AID-def.20	Kuweit	M	1.5	16	408	40	<30	lymphoid hyperplasia, recurrent infections	254G>A / 254G>A	S85N / S85N	AR
AID-def.22*	Kuweit	M	3	14	1800	< 7	< 7	lymphoid hyperplasia, recurrent infections	254G>A / 254G>A	S85N / S85N	AR
AID-def.23*	Kuweit	M	8.5	13	677	< 6	< 33	lymphoid hyperplasia, recurrent infections	254G>A / 254G>A	S85N / S85N	AR
AID-def.26	French	M	6	10	140	<7	<7			C87R / C147X	AR
AID-def.27	French Canadian	M							334C>T / 334C>T	R112C / R112C	AR
AD- <i>AICDA</i> 12	French	F	71	76	203	<7	130	recurrent infections	568C>T / Normal	R190X / Normal	AD
AD- <i>AICDA</i> 13	Japan	M							568C>T / Normal	R190X / Normal	AD
AD- <i>AICDA</i> 14	Japan	F		58					568C>T / Normal	R190X / Normal	AD
AD- <i>AICDA</i> 18	Turkish	M		17					559del/ Normal	V186X/ Normal	AD
<i>AICDA</i> ^{+/+} 1M	Moroccan	F		adult				healthy	203G>A/ Normal	W68X/ Normal	HET
<i>AICDA</i> ^{+/+} 1F	Moroccan	M		adult				healthy	175-184 del	H25-E58 del insV/ Normal	HET
<i>AICDA</i> ^{+/+} 6F	Pakistani	M		adult				adult	394G>C / Normal	A132P / Normal	HET
<i>AICDA</i> ^{+/+} 6M	Pakistani	F		adult				adult	394G>C / Normal	A132P / Normal	HET
<i>AICDA</i> ^{+/+} 17F	Turkish	M		adult				healthy	415 A>G/ Normal	M139V/ Normal	HET
<i>AICDA</i> ^{+/+} 17M	Turkish	F		adult				healthy	415 A>G/ Normal	M139V/ Normal	HET
<i>AICDA</i> ^{+/+} 19F	Kuweit	M		35				healthy	254 G>A/ Normal	S85N/ Normal	HET
<i>AICDA</i> ^{+/+} 20F	Kuweit	M		48				healthy	254 G>A/ Normal	S85N/ Normal	HET
<i>AICDA</i> ^{+/+} 22M	Kuweit	F		33				healthy	254 G>A/ Normal	S85N/ Normal	HET
<i>AICDA</i> ^{+/+} 26M	French	F		41				healthy		C87R/ Normal	HET
<i>AICDA</i> ^{+/+} 27B	French Canadian	M		57				healthy	334C>T / Normal	R112C / Normal	HET
<i>AICDA</i> ^{+/+} 27S	French Canadian	F		47				healthy	334C>T / Normal	R112C / Normal	HET
UNG-def.1	USA	M	39	40	785	<7	209	lymphoid hyperplasia, recurrent infections	497,498 AT del/497,498 AT del	frameshift	
UNG-def.2	Japan	F	3	12	267	25	<50	HIGM	T822C/T822C	F251S/F251S	
UNG-def.3	French	M	7	26	740	48	50	HIGM	462 C del/639,640 TA del	frameshift	

* siblings

AD: autosomal dominant

HET: heterozygote

Supplementary Table 2, related to Figure 1. Repertoire and reactivity of antibodies from new emigrant B cells of HD30

Ig	HEAVY					LIGHT					REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	HEp-2	Staining
neHD30 K3	4-39	5-12	2	4	PSLSGYDYSLDY	12	3-20	3	QQYGSSPLFT	10	-	-	-
neHD30 K4	3-15	/	/	3	GGGVGAFDI	9	2-28	5	MQALQTPT	8	-	-	c
neHD30 K5	3-30-3	1-26	2	6	QSSPTGGGMDV	11	1-5	2	QQYNSYSY	9	-	+	-
neHD30 K10	4-4	3-9	3	5	VSNHILTNRLFDP	14	3-20	1	QQYGSSPRT	9	-	+	-
neHD30 K12	1-2	2-15	2	3	HPIGYCSGGSCYGGAFDI	18	1-33	4	QQYDNLPT	8	-	-	-
neHD30 K14	4-34	3-10	3	2	KGTMVRGVIIIPHWFYDL	18	2-28	1	MQALQTPQT	9	-	+	-
neHD30 K16	3-30	/	/	6	EGVSHYYGMDV	12	2-28	4	MQALQTPPT	9	-	-	-
neHD30 K20	3-30	4-17	2	6	DIHRDYGDIETPNYYYYGMDV	21	1-9	1	QQLNSYPLA	9	-	+	-
neHD30 K24	3-72	/	/	6	DNRGMDV	7	4-1	4	QQYYSTPLT	9	-	-	-
neHD30 K26#	1-18	3-16	2	4	NYDYIWGSYFTRGGY	15	1-33	3	QQYDNLPLFT	10			
neHD30 K43	3-9	3-22	2	2	VDSSGLFGWYFDL	13	3-20	1	QQYGSSPQT	9	-	-	-
neHD30 K45#	3-15	2-15	3	4	DPLIVVVVAATRDFDY	16	1-39	2	QQSYSTPYT	9			
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	HEp-2	Staining
neHD30 L7	4-59	/	/	4	DRNFDY	6	3-1	2	QAWDSSTAV	9	-	-	-
neHD30 L11	3-33	/	/	4	GGGGGDY	7	2-14	2	SSFTSITYVW	10	-	-	-
neHD30 L19	3-11	1-7	2	4	DRGNNGRNPNWNYFFDY	18	2-14	1	SSYTSSTLLYV	12	-	+	-
neHD30 L21#	3-53	4-17	2	4	VGRYGDYAYTISRYYFDY	20	2-14	2	SSYTSSTLGV	11			
neHD30 L28	3-15	1-26	1	6	AGITKFWELPGYYYGMDV	19	1-44	3	AAWDDSLNVVW	11	-	-	-
neHD30 L30	3-23	2-21	3	6	GEGGVVTTQALMDV	15	1-44	2	AAWDDSLNGVV	11	-	-	-
neHD30 L42	1-69	4-4	2	6	SDYSNYVLYDYYYYYGMDV	19	2-8	2	SSYAGSNNLV	10	+	-	-
	VH	D	RF	JH	CDR3(aa)	Length							
neHD30 H2	4-34	3-10	2	4	GQDYYGSGSTADY	13							
neHD30 H29	3-23	6-13	2	4	DEVSSSWLFGY	11							
neHD30 H38	3-72	3-10	1	6	AGSWWFGETRYGMDV	15							
neHD30 H41	3-23	5-12	2	4	VRGRPDGSGYRFDY	13							
neHD30 H44	1-69	2-15	2	6	GSYCSCGSCYSSFYYYYGMDV	21							
neHD30 H46	3-21	/	/	6	DDNLPIDYGMDV	12							

RF, reading frame; #, antibody failed to be expressed

-, non-reactive; +, reactive;

c, diffuse cytoplasmic staining; N, nuclear staining; F, cytoplasmic fibers; V, vesicles

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----

© 2010 Microsoft Corporation. All rights reserved. Microsoft, the Microsoft Dynamics logo, and "Your business. Your data." are either registered trademarks or trademarks of Microsoft Corporation in the United States and/or other countries.

Supplementary Table 4, related to Figure 6 and 7. Repertoire and reactivity of antibodies from new emigrant B cells of NSG mice

Ig	HEAVY						LIGHT				REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	V _k	J _k	CDR3(aa)	Length	Poly	HEp2	Staining
neM1 K2	1-3	1-7	2	4	DLELYYFDY	9	3-20	1	QQYGSSPT	8	-	-	-
neM1 K5	4-30-2	3-10	2	4	ISGSYYNY	8	1-39	1	QQSYSTPWT	9	-	+	-
neM1 K8	4-59	3-9	2	4	SPPFDWIYFDY	12	3-20	1	QQYGSSPWT	9	-	-	-
neM1 K9	3-73	4-23	2	4	RYGGNYFDY	10	3-11	4	QQRSNWPLT	9	-	+	-
neM1 K10	3-15	1-26	1	3	QTEWELDAFDI	11	3-20	4	QQYGSSPPLT	10	-	-	-
neM1 K11	3-74	3-10	2	6	DPGKGYGSGSYYYYGMDV	20	1-6	2	LQDYNYPYT	9	-	-	-
neM1 K16	4-30-2	/	/	3	TNEPNAFDI	9	2-28	4	MQALQTPLT	9	-	-	-
neM1 K22	4-4	3-22	2	3	DRADYYDSSGYYYAFDI	17	1-17	4	LQHNSYPPT	9	-	-	-
neM1 K23	3-7	1-26	2	6	NRPPGAINYYGMDV	14	3-11	1	QQRSNWPWT	9	-	-	-
neM1 K25	4-34	1-26	3	4	GGGATEY	7	1-17	1	LQHNSYLWT	9	-	-	-
neM1 K32	4-59	/	/	3	THPQSDAFDI	10	2-30	4	MQGTHWPLT	9	-	+	-
neM1 K33#	3-7	3-10	3	3	ILGGITMVRGAEDAFDI	17	3-20	1	QQYGSSPRT	9			
neM1 K37	3-30	3-10	1	4	EKGWFGELEGLAIDY	15	3-15	1	QQYNNWPQT	9	-	-	-
neM1 K38	4-34	7-27	2	2	GLTGDSGTDWYFDL	14	1-39	4	QQSYSTPLT	9	-	-	-
neM1 K40	4-39	6-13	2	4	HPYSSSFYD	9	3-20	2	QQYGSSYT	8	-	-	-
neM1 K42	3-33	3-10	2	6	DPRLGSGSYYYYGMDV	16	1-39	3	QQSYSTPFT	9	-	+	-
neM1 K43#	4-30-4	7-27	2	4	NKLNWGLDY	9	1-5	1	QQYNSYSPWT	10			
neM1 K45	4-4	7-27	2	5	GWGFGNWFDP	10	3-20	2	QQYGSSPPYT	10	-	-	-
neM1 K46	4-59	/	/	4	SFSRLASFDY	10	3-20	1	QQYGSSLGT	9	-	-	-
neM1 K48	4-59	/	/	4	VGGRGGDFDY	10	1-33	3	QQYDNLPRVT	10	-	-	-
	VH	D	RF	JH	CDR3(aa)	Length	V _λ	J _λ	CDR3(aa)	Length	Poly	Hep2	Staining
neM1 L1	3-30	6-13	2	4	SGSSWYFDY	10	2-14	2	SSYTSSSTV	9	-	-	-
neM1 L3	1-69	/	/	4	VMAVYFDY	9	1-40	1	QSYDSSLGGYV	11	+	+	-
neM1 L6	3-30-3	3-16	2	4	GPSRGGEVFDY	11	3-21	3	QVWDSSSDQNWV	12	-	-	-
neM1 L7	5-51	3-22	2	4	LRIPDYDSSGYYFDY	15	2-8	3	SSYAGSNNLV	10	-	-	-
neM1 L12	4-4	/	/	4	GSIPSDYFDY	11	3-25	2	QSADSSGTYPV	11	-	-	-
neM1 L13#	1-69	6-13	2	5	TIYSSSWYWFDP	12	5-37	2	MIWPSNAYVV	10			
neM1 L14	3-30	3-22	2	2	DYYDSSGYYYWYFDL	15	1-44	2	AAWDDSLNGPV	11	-	+	+
neM1 L24	3-13	6-13	2	3	GGRDSSWYIAFDI	13	2-23	1	CSYAGSSTYV	10	-	+	-
neM1 L26	1-3	7-27	2	5	GQTTNLGMGNWFDP	15	1-40	2	QSYDSSLGGVV	11	-	-	-
neM1 L27	3-23	2-15	2	3	DPLSRYCSGGSCYGAFDI	19	1-44	2	AAWDDSLNGHV	12	-	-	-
neM1 L28	1-18	6-19	3	4	GIAVAGYFDY	10	2-8	2	SSYAGSNNLV	10	-	-	-
neM1 L30	3-7	/	/	4	DRLGSFDY	8	1-47	3	AAWDDSLGGVV	11			
neM1 L31	3-33	3-9	2	4	DAALRYFDWLLDY	13	2-14	1	SSYTSSSTLV	10	-	-	-
neM1 L34	3-7	/	/	4	DLVGIRATDY	10	1-51	1	GTWDSSLSAYV	11	-	+	-
neM1 L35	3-30	6-13	3	1	DVNAAAGNRAYFQH	14	3-21	1	QVWDSSSDHYV	11	-	-	-
neM1 L36	3-30	1-26	2	4	DGDSGSYFDY	10	2-23	2	CSYAGSSTYVV	11	-	-	-
neM1 L39	3-30-3	7-27	1	3	VCSPELGQWIDI	12	3-21	2	QVWDSSSDHV	11	-	+	-
neM1 L41	3-15	3-16	2	3	DWGTRAFDI	9	1-51	3	GTWDSSLSAGV	11	-	-	-
	VH	D	RF	JH	CDR3(aa)	Length							
neM1 H4	3-64	6-19	3	4	GIVAVAGNLDY	11							

Supplementary Table 5, related to Figure 6 and 7. Repertoire and reactivity of antibodies from new emigrant B cells of AIDshRNA treated I

Ig	HEAVY						LIGHT				REACTIVITY		
	VH	D	RF	JH	CDR3(aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	Hep2	Staining
neGFP+M5 K3	1-46	4-23	2	1	KPNYGANQYFQH	12	3-20	3	QQYGSSPLT	9	+	+	n
neGFP+M5 K10	3-7	5-5	2	3	DSVRYSYGTDAFDI	14	1-37	4	QRTYNAPLT	9	-	-	-
neGFP+M5 K11	3-30	5-5	3	5	DRDTAMVTWFDP	12	1-5	1	QQYNSYSWT	9	+	-	-
neGFP+M5 K14	3-7	6-19	2	4	APLRWEYSSGWYGDY	15	3-15	1	QQYNNWPPWT	10	-	+	-
neGFP+M5 K16#	1-2	6-13	2	4	SPRSWYDY	8	3-20	5	QQYGSSPTT	9			
neGFP+M5 K18	5-51	6-13	2	3	YSSSWWGAFDI	11	2-30	1	MQGTHWPPT	9	+	-	-
neGFP+M5 K19	3-30-3	1-26	1	6	DRENGGAWERYLGMDV	16	3-20	1	QQYGSSPT	8	+	+	-
neGFP+M5 K20	3-15	1-7	2	2	GPNYPNQSRYFDL	13	3D-15	4	QQYNNWPPAPFT	12	+	+	n
neGFP+M5 K21	3-33	2-21	2	4	EAYCGGDCYFPWDY	14	1-5	2	QQYNSYSHT	9	-	+	c
neGFP+M5 K22	5-a	6-6	2	3	PHEYSSSDAFDI	13	1-5	1	QQYNSYST	8	-	+	-
neGFP+M5 K23	4-61	4-17	2	4	ESGDYFFDY	9	4-1	2	QQYYSTPYT	9	-	-	-
neGFP+M5 K25#	4-39	6-13	3	3	WYGAFDI	7	3-15	1	QQYNNWLTWT	10			
neGFP+M5 K27	4-61	/	/	3	KPNIPDAFDI	10	1-39	1	QSYSTPGP	9	-	-	-
neGFP+M5 K28	1-69	3-22	2	4	DYYDSSGYPPFDY	13	3-20	2	QQYGSSPYT	9	+	-	-
neGFP+M5 K29	3-30	4-17	2	4	DLKVRTYDYGDNYY	16	1-17	1	LQHNSYPWT	9	-	+	-
neGFP+M5 K31	4-34	3-22	2	3	GVYYDSSGYSNDAFDI	16	3-11	2	QQRSNWYT	8	-	-	-
neGFP+M5 K33	4-34	6-13	3	5	GKGIAAGYNWFDP	14	3-15	1	QQYNNWLTWT	10	+	+	-
neGFP+M5 K34	3-33	3-22	2	4	DAHYYDSSGYPPAYFDY	18	1-5	3	QQYNSYLFT	9	-	+	-
neGFP+M5 K38	3-33	/	/	4	GQTVFDY	7	3-15	2	QQYNNWPYT	9	-	+	n
neGFP+M5 K42	4-34	3-16	1	4	GPAGELSLDY	10	3-11	5	QQRSNWLPIT	10	-	+	-
neGFP+M5 K48	3-33	3-16	3	4	DLYRVTFGGAIDY	13	1-5	2	QQYNSYPWT	9	-	+	-
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	Hep2	Staining
neGFP+M5 L5	3-23	4-17	2	2	DGYGDYIYWFYFDL	12	1-40	2	QSYDSSLSGSV	11	-	-	-
neGFP+M5 L7	3-64	/	/	4	WAGLGSYFFDY	11	3-21	2	QVWDSSSDHVV	11	-	-	-
neGFP+M5 L8	3-15	6-13	2	6	DRDSSSWTTYYYYYYMDV	18	2-14	1	SSYTSSSTLV	10	-	-	n
neGFP+M5 L9#	3-7	6-19	2	3	GRSSGWFAFDI	12	3-21	2	QVWDSSSDHPV	11			
neGFP+M5 L12	3-7	3-10	2	6	DTTYYGSGSYSDYYYYYMDV	21	1-51	2	GTWDSSLSAGV	11	-	+	-
neGFP+M5 L15	4-34	3-22	2	4	GYSDSSGVDY	10	2-14	3	SSYTSSSTLG	10	-	-	n
neGFP+M5 L24	3-64	3-3	2	2	DSSKDFWSGPWYFDL	15	2-14	2	SSYTSSSTLVV	11	-	-	-
neGFP+M5 L30	1-3	7-27	2	4	DSLGLDLPFDY	11	2-11	2	CSYAGSYTLV	10	-	+	-
neGFP+M5 L32#	3-30	6-19	2	4	VTSYSSGWYIGIDY	13	2-14	2	SSYTSSSTLV	10			
neGFP+M5 L37	5-51	6-13	3	4	GIAAAGPFYD	10	1-44	1	AAWDDSHYV	9	-	-	-
neGFP+M5 L38					see Kappa		3-25	2	QSADSSGTYYV	11	-	+	-
neGFP+M5 L39	3-30	/	/	6	FHGDYYGMDV	10	3-21	1	QVWDSSSDHYV	11	+	+	-
neGFP+M5 L40	3-30	6-19	3	4	DHHRIVADLFDY	13	3-21	2	QVWDSSSDHVV	11	-	-	-
neGFP+M5 L41	4-34	2-8	2	4	HRNCTNGVCYFDY	13	2-8	2	SSYAGSNNVV	10	-	-	-
neGFP+M5 L43	4-4	3-3	1	3	RFLEWLECAFDI	12	1-51	2	GTWDSSLSAVV	11	-	+	-
neGFP+M5 L46#	1-3	6-13	3	6	DGELNAAAAGYYYYGMDV	18	1-47	3	AAWDDSLSGWV	11			
neGFP+M5 L13							2-14	3	SSYTSSSIWV	10			
	VH	D	RF	JH	CDR3(aa)	Length							
neGFP+M5 H6	3-11	6-13	2	4	VYDSSTYYFDY	11							
neGFP+M5 H45	1-18	6-13	3	4	DLAAAGHGGY	10							

Supplementary Table 6, related to Figure 6 and 7. Repertoire and reactivity of antibodies from new emigrant B cells of PFTα treated NSG mic

Ig	HEAVY					LIGHT				REACTIVITY			
	VH	D	RF	JH	CDR3(aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	Hep2	Staining
neM9-PFTa K3	5-10	2-2	2	4	HVGYCSSTSCDDY	13	1-17	1	LQHNSYPWT	9	+	-	-
neM9-PFTa K8	3-7	2-8	2	2	VVDLPILGYCTGGVCDKRGWYFDL	24	3-20	2	QQYGSSPQYT	10	+	+	-
neM9-PFTa K16	4-39	3-10	2	5	TWRGSGSYNNATTKDWFDP	20	3-15	1	QQYNNWPQT	9	+	+	-
neM9-PFTa K17	3-23	2-2	2	4	EDCSSTSCFDYFDY	14	3-20	3	QQYGSSPLFT	11	-	-	-
neM9-PFTa K20	3-23	6-13	3	3	DRSIAAAGTGAAFDI	15	1-5	1	QQYNSYFWT	9	-	+	-
neM9-PFTa K27	3-48	/	/	4	SFLGLKWVDY	10	3-15	1	QQYNNWPQT	9	+	+	c
neM9-PFTa K36	4-34	7-27	2	6	EVTNWGSYYMDV	13	1-8	4	QQYYSYPRS	9	+	+	-
neM9-PFTa K37	3-7	2-15	2	4	SSGGYCSGGSCYTLPYYFDY	20	3-20	2	QQYGSSPRYT	10	-	+	n
neM9-PFTa K41	1-69	2-21	2	3	GAYCGGDCNDAFDI	14	3-20	2	QQCGSSPYT	9	-	-	-
neM9-PFTa K42	4-39	6-13	3	2	DVLLAAAGNDWYFDL	15	1-5	2	QQYNSYSRT	9	+	-	-
neM9-PFTa K44	3-7	5-12	3	4	DGGRVATRATSFYD	14	3-15	2	QQYNNWPPMYT	11	-	-	-
neM9-PFTa K45	3-23	/	/	4	DSGWGAFDY	9	1-39	4	QQSYSTPQRDLT	13	+	+	-
	VH	D	RF	JH	CDR3(aa)	Length	Vλ	Jλ	CDR3(aa)	Length	Poly	Hep2	Staining
neM9-PFTa L1	3-30	4-17	2	4	DEGLLAYFDDYGDYCPGDY	19	1-47	3	AAWDDSLSGWV	11	-	+	-
neM9-PFTa L3					see κ-chain	11	2-11	3	CSYAGSYTWV	10			
neM9-PFTa L6	1-2	6-6	2	4	DRAPFRSSSPHFYD	14	3-21	2	QVWDSSSDHVV	11	-	+	-
neM9-PFTa L7	1-18	/	/	4	ASTRYGADY	9	1-51	3	GTWDSSLSAWV	11	-	+	-
neM9-PFTa L9	3-23	/	/	4	VPYPQYYFDY	10	3-25	2	QSADSSGTSVV	11	-	-	-
neM9-PFTa L10	3-23	2-2	3	3	LVVPAAMRDAFDI	13	2-8	2	SSYAGSNIVV	10	-	-	-
neM9-PFTa L11	3-23	2-21	2	5	GAYCGGDCLLDWFDP	15	2-11	1	CSYAGSYTYV	10	+	+	-
neM9-PFTa L12#	4-34	3-10	2	4	GGDYGSGSYLFNRIQGSKGFYYFDY	28	2-23	1	CSYAGSYV	8			
neM9-PFTa L18	3-23	6-13	3	4	QPAAGDY	7	2-14	2	SSYTSSTVV	10	-	-	-
neM9-PFTa L22	1-18	7-27	1	4	VLLPIGLGMDY	11	1-51	1	GTWDSSLSAYV	11			
neM9-PFTa L24	4-61	3-10	3	4	EARVRRQGVIITSPYFDY	18	1-44	1	AAWDDSLNGPV	11	-	+	-
neM9-PFTa L25#	3-53	6-13	2	6	SGSSSSLHYYYMDV	15	2-23	1	CSYAGSSPNYV	11			
neM9-PFTa L30#	1-3	6-6		6	GTDIAARPSEGYYYYGMDV	19	2-14	1	SSYTSSTYV	10			
neM9-PFTa L33#	4-34	2-2	3	4	VTDIVVPAAPRSPPCFDY	19	1-51	2	GTWDSSLSAVV	11			
neM9-PFTa L45					see κ-chain	13	1-40	2	QSYDSSLSGSV	11	-	-	-
neM9-PFTa L46	3-30	4-4	2	4	EGDYSNLAWRRYFDY	15	2-8	1	SSYAGSNIVV	10	-	-	-
neM9-PFTa L47	3-11	3-10	1	5	GGGVLFRELLNNWFDP	17	2-14	2	SSYTSSTVV	10	+	+	-
	VH	D	RF	JH	CDR3(aa)	Length	Vκ	Jκ	CDR3(aa)	Length	Poly	HEp2	Staining
neM10-PFTa K3	3-21	1-26	2	4	EQNSGSYYY	9	1-39	1	QQSYSTTWT	9	+	+	n
neM10-PFTa K8	3-30-3	1-26	2	4	VCVGSYYFDY	10	1-39	3	QQSYSTPFT	9	+	+	-
neM10-PFTa K9	1-2	6-13	3	3	DLRIAAAGDAFDI	13	3-15	5	QQYNNWPIT	9	-	+	-